OUP accepted manuscript

医学 德诺苏马布 置信区间 危险系数 临床终点 刮除术 外科 辅助治疗 随机对照试验 内科学 骨质疏松症 化疗
作者
Hiroshi Urakawa,Akihito Nagano,Ryunosuke Machida,Kazuhiro Tanaka,Tomoko Kataoka,Yuta Sekino,Yoshihiro Nishida,Mitsuru Takahashi,Toshiyoshi Fujiwara,Masanori Kawano,Yukihiro Yoshida,Tatsuya Takagi,Kenji Sato,Toru Hiruma,Hiroshi Hatano,Satoshi Tsukushi,Akio Sakamoto,Toshihiro Akisue,Koji Hiraoka,Toshiyoshi Fujiwara
出处
期刊:Japanese Journal of Clinical Oncology [Oxford University Press]
标识
DOI:10.1093/jjco/hyac071
摘要

The aim of JCOG1610 (randomized controlled phase III trial) was to confirm the superiority of preoperative denosumab to curettage with adjuvant local therapy for patients with giant cell tumor of bone without possible post-operative large bone defect.The primary endpoint was relapse-free survival and the total sample size was set at 106 patients. Patient accrual began in October 2017. However, the accrual was terminated in December 2020 due to a recommendation from the Data and Safety Monitoring Committee because of poor patient accrual. Now, we report the descriptive results obtained in this study.A total of 18 patients had been registered from 13 Japanese institutions at the time of termination on December 2020. Eleven patients were assigned to Arm A (curettage and adjuvant local therapy) and 7 to Arm B (preoperative denosumab, curettage and adjuvant local therapy). Median follow-up period was 1.6 (range: 0.5-2.8) years. Protocol treatment was completed in all but one patient in Arm A who had a pathological fracture before surgery. All patients in Arm B were treated with five courses of preoperative denosumab. Relapse-free survival proportions in Arm A and B were 90.0% (95% confidence interval: 47.3-98.5) and 100% (100-100) at 1 year, and 60.0% (19.0-85.5) and 62.5% (14.2-89.3) at 2 years, respectively [hazard ratio (95% confidence interval): 1.51 (0.24-9.41)].In terms of relapse-free survival, the superiority of preoperative denosumab was not observed in patients with giant cell tumor of bone without possible post-operative large bone defect.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
2秒前
3秒前
王露阳完成签到,获得积分10
5秒前
7秒前
香蕉觅云应助Yexidong采纳,获得10
7秒前
一叶知秋应助zz采纳,获得20
8秒前
Jun发布了新的文献求助10
8秒前
8秒前
9秒前
水的温度完成签到,获得积分10
9秒前
10秒前
12秒前
13秒前
不懂发布了新的文献求助10
14秒前
14秒前
15秒前
17秒前
隐形曼青应助lx采纳,获得10
18秒前
大观天下发布了新的文献求助10
20秒前
Layqiwook完成签到,获得积分10
24秒前
Hayat发布了新的文献求助30
26秒前
聂难敌完成签到,获得积分10
28秒前
lance发布了新的文献求助10
31秒前
cctv18应助科研通管家采纳,获得10
34秒前
九耳兔发布了新的文献求助10
35秒前
gjww应助科研通管家采纳,获得10
35秒前
小蘑菇应助科研通管家采纳,获得10
35秒前
FashionBoy应助科研通管家采纳,获得10
35秒前
科研通AI2S应助科研通管家采纳,获得10
35秒前
35秒前
35秒前
汉堡包应助Yangzx采纳,获得10
35秒前
宏、发布了新的文献求助10
35秒前
Ashmitte完成签到,获得积分10
36秒前
36秒前
Lucas应助小壳儿采纳,获得10
36秒前
37秒前
39秒前
Singularity应助tingtingliuok采纳,获得10
39秒前
高分求助中
Sraffa and applied economics: are there classical supply curves? 1000
Heun’s Differential Equations 600
《Fundamentals of Power Supply Design》Robert A. Mammano 510
谁能看见前面有梦可想 500
Wind Effects on Structures: An Introduction to Wind Engineering and Wind Forces in Engineering (2nd Edition) 300
Against the Grain: The Vayda Tradition in Human Ecology and Ecological Anthropology 300
High Wire: How China Regulates Big Tech and Governs Its Economy 260
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2248820
求助须知:如何正确求助?哪些是违规求助? 1898113
关于积分的说明 4732738
捐赠科研通 1687209
什么是DOI,文献DOI怎么找? 856182
版权声明 545086
科研通“疑难数据库(出版商)”最低求助积分说明 453077